Avalo Therapeutics (AVTX) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CorMedix (CRMD) has outperformed Avalo Therapeutics (AVTX) over the past year, losing 45.6% versus a loss of 62.1%. Over five years, CRMD leads with a +3.9% price change compared with -99.9% for AVTX. CorMedix is the larger company by market cap ($419.2 million vs $390.9 million), about 1.1 times the size.
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -132642.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | CRMD |
|---|---|---|
| Share price | $6.76 | $5.27 |
| Market cap | $390.88M | $419.16M |
| 1-day change | +0.15% | +3.74% |
| YTD return | -62.78% | -54.69% |
| 1-year return | -62.09% | -45.56% |
| 5-year return | -99.89% | +3.94% |
| P/E ratio (TTM) | — | 8.23 |
| Forward P/E | — | 15.06 |
| EPS (TTM) | $-2.26 | $0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | $311.71M |
| Revenue growth (YoY) | -86.62% | +617.03% |
| Net income (latest FY) | $-78.26M | $163.06M |
| Gross margin | — | 88.46% |
| Operating margin | -123601.69% | 48.17% |
| Net margin | -132642.37% | 52.31% |
| 52-week high | $24.27 | $13.02 |
| 52-week low | $6.53 | $4.47 |
| Distance from 52-week high | -72.15% | -59.52% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +414.79% | +161.86% |
| Average volume | 1.80M | 1.44M |
| Shares outstanding | 57.82M | 79.54M |
| Employees | 33 | 191 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRMD has outperformed AVTX by 16.5 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -86.62%).
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
AVTX vs CRMD FAQ
Which is bigger, Avalo Therapeutics or CorMedix?
CorMedix (CRMD) is larger, with a market capitalization of $419.16M compared with $390.88M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or CRMD?
CRMD returned -45.56% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.